The future of osteoarthritis therapeutics: targeted pharmacological therapy

Mobasheri, Ali (2013) The future of osteoarthritis therapeutics: targeted pharmacological therapy. Current Rheumatology Reports, 15 (10). 13/1-13/13. ISSN 1523-3774

[img] PDF - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
Available under Licence Creative Commons Attribution.
Download (341kB)

Abstract

Osteoarthritis (OA) is one of the most common forms of degenerative joint disease and a major cause of pain and disability affecting the aging population. It is estimated that more than 20 million Americans and 35 to 40 million Europeans suffer from OA. Analgesics and non-steroidal anti-inflammatory drugs (NSAIDs) are the only therapeutic treatment options for OA. Effective pharmacotherapy for OA, capable of restoring the original structure and function of damaged cartilage and other synovial tissue, is urgently needed, and research into such disease-modifying osteoarthritis drugs (DMOADs) is in progress. This is the first of three reviews focusing on OA therapeutics. This paper provides an overview of current research into potential structure-modifying drugs and more appropriately targeted pharmacological therapy. The challenges and opportunities in this area of research and development are reviewed, covering the most up-to-date initiatives, trends, and topics.

Item Type: Article
Keywords: Osteoarthritis, Therapeutics, Pharmaceuticals, Pharmacological therapy, Analgesics, Non-steroidal anti-inflammatory drugs (NSAIDs), Bisphosphonates, Strontiumranelate, Inducible nitric oxide synthase (iNOS), Anti-MMPtherapy, DMOADs, Biomarkers
Schools/Departments: University of Nottingham UK Campus > Faculty of Medicine and Health Sciences > School of Veterinary Medicine and Science
Depositing User: Johnson, Mrs Alison
Date Deposited: 04 Apr 2014 10:09
Last Modified: 14 Sep 2016 08:39
URI: http://eprints.nottingham.ac.uk/id/eprint/2863

Actions (Archive Staff Only)

Edit View Edit View